Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group
Pratteln, Switzerland, January 6, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® ...
Pharmabiz1d
Santhera enters supply and distribution agreement with Clinigen Group for Agamree to treat patients with Duchenne muscular dystrophy
Pratteln, Switzerland Tuesday, January 7, 2025, 11:00 Hrs [IST] ...
The Pharma Letter2d
Santhera partners with Clinigen to expand Agamree access
Santhera partners with Clinigen to supply Agamree for Duchenne muscular dystrophy in regions without commercial availability.
pharmaphorum3d
Clinigen educates on early access to rare disease therapies
On Rare Disease Day, Clinigen has launched a campaign to try to encourage doctors and patients to explore how they can get early access to investigational therapies. The ‘What is Possible?’ ...
pharmaphorum1y
Clinigen launches scheme to support rare disease patients
Clinigen has launched a new programme in the ... after going into private hands when it was acquired for £1.3 billion by investment group Triton last year. "I am thrilled to see the launch ...
Investors Chronicle11y
Clinigen makes solid start
With the pandemic well and truly a thing of the past, now is the perfect time to reconsider these un ...
Investors Chronicle11y
Clinigen delivers a profitable niche
Clinigen's rapid growth coincides with the prevailing trend for pharma companies to outsource more functions. Independent forecasters reckon that supplying drugs for trials in Europe and the US alone ...